Higher Opioid Use After Bariatric Surgery Did Not Prove Cannabis Caused Tolerance

A surgical cohort found higher perioperative opioid use among patients reporting marijuana use. The finding did not independently establish that cannabis caused opioid tolerance, and the accompanying pain-score difference was not statistically significant.

The comparison involved existing cannabis use

The study included 434 bariatric-surgery patients, thirty-six of whom reported marijuana use. Investigators analyzed perioperative opioid requirements and other outcomes. Cannabis use was not randomly assigned.

The statistical results differed

Opioid requirements were significantly higher in the marijuana-user group. Reported pain scores were numerically lower, but the abstract gives a p value of 0.07 for that comparison. A numerical difference at that value should not be presented as a significant reduction in pain.

Other outcomes did not show an association

The abstract reported no effect on ninety-day weight loss, postoperative complications or improvement in medical comorbidities in this cohort. These negative findings do not establish equivalence or exclude smaller differences, particularly with a relatively small cannabis-user group.

Higher opioid administration could reflect several clinical and patient factors. It is not a direct receptor-tolerance assay, and it does not by itself prove greater pain sensitivity or a causal drug interaction. The useful distinction is between a measured treatment requirement and a proposed explanation for it. The study can inform further investigation without determining an individual patient's medication needs or proving that cannabis caused a particular postoperative outcome.

Related: interpreting cannabis tolerance claims.

Research cited

Bauer FL; Donahoo WT; Hollis HW; Tsai AG; Pottorf BJ; Johnson JM; Silveira LJ; Husain FA. Marijuana's Influence on Pain Scores, Initial Weight Loss, and Other Bariatric Surgical Outcomes. The Permanente journal (2018). doi:10.7812/TPP/18-002. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Psychiatric CBD Review’s Recommendation Grades Included Both CBD and THC-Containing Nabiximols

A review published in 2020 graded psychiatric evidence from studies of CBD and CBD-containing nabiximols. Its recommendation labels should not be quoted as though every underlying intervention was purified CBD or every study was randomized. The included designs ranged widely The review identified 23 relevant studies spanning case reports, case…

Spread the love

Read Article: A Psychiatric CBD Review’s Recommendation Grades Included Both CBD and THC-Containing Nabiximols

CBD Eye Research: Molecular Targets and Clinical Ocular Treatment Are Different Evidence Levels

A 2021 ocular CBD review brought together in-vitro and in-vivo research, proposed molecular targets and possible therapeutic applications. This evidence maps a development pathway; it does not establish that CBD products are effective eye treatments. The experimental system belongs in the conclusion A cellular result can identify a target or…

Spread the love

Read Article: CBD Eye Research: Molecular Targets and Clinical Ocular Treatment Are Different Evidence Levels

CBD Addiction Research Measures Reinforcement, Motivation and Withdrawal as Different Outcomes

A 2021 review evaluated CBD research on reinforcing, motivational and withdrawal-related drug effects. These outcomes can inform substance-use-disorder research, but an improvement in one cannot establish successful treatment across all of them. The source combined preclinical and clinical reports The review covered alcohol, opioids, cannabinoids, nicotine and psychostimulants. An animal…

Spread the love

Read Article: CBD Addiction Research Measures Reinforcement, Motivation and Withdrawal as Different Outcomes

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us